Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,471.2141 pence per share.
Material Changes
- Share Repurchase: On April 17, 2007, the Company purchased 600,000 ordinary shares of 25 pence each.
- Treasury Holdings: Following this transaction, the Company holds 286,742,678 shares in Treasury.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) is 5,727,771,369.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Points
- Verify the total number of shares in issue (5,727,771,369) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (286,742,678) for accurate fully diluted share count calculations.
- Note that this filing is a notification of a specific transaction and does not include periodic financial performance results.